Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. Lynch, R. C., Bendell, J. C., Advani, R. H., Falchook, G., Munster, P. N., Patel, M. R., Gutierrez, M., Burness, M., Palmisiano, N., Hamadani, M., Bradley, W. D., O'Shea, T. J., Doleman, S., Renschler, M., Englert, J. M., Yap, T. A. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.3006
View details for Web of Science ID 000708120601183